KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report)'s share price rose 8.3% on Monday . The company traded as high as $11.74 and last traded at $11.60. Approximately 531,267 shares changed hands during mid-day trading, an increase of 35% from the average daily volume of 392,121 shares. The stock had previously closed at $10.71.
Analyst Upgrades and Downgrades
Several equities research analysts have commented on the stock. Jones Trading reissued a "buy" rating and set a $30.00 price target on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Bank of America started coverage on KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They issued a "buy" rating and a $22.00 price target for the company. JMP Securities began coverage on KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an "outperform" rating and a $19.00 price target on the stock. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Finally, Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 31st. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $24.83.
View Our Latest Analysis on KalVista Pharmaceuticals
KalVista Pharmaceuticals Trading Up 9.0 %
The business has a 50 day moving average of $11.07 and a two-hundred day moving average of $10.30. The firm has a market cap of $571.24 million, a P/E ratio of -3.16 and a beta of 0.39.
Insider Activity
In other news, CEO Benjamin L. Palleiko sold 5,104 shares of KalVista Pharmaceuticals stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total transaction of $50,121.28. Following the completion of the sale, the chief executive officer now owns 278,855 shares of the company's stock, valued at approximately $2,738,356.10. This trade represents a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Paul K. Audhya sold 3,125 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total transaction of $30,687.50. Following the completion of the sale, the insider now directly owns 100,334 shares of the company's stock, valued at approximately $985,279.88. The trade was a 3.02 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have purchased 261,055 shares of company stock valued at $2,397,646 and have sold 17,292 shares valued at $184,625. Insiders own 10.50% of the company's stock.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in KALV. Boxer Capital Management LLC acquired a new position in KalVista Pharmaceuticals in the fourth quarter valued at about $13,467,000. Octagon Capital Advisors LP acquired a new position in shares of KalVista Pharmaceuticals in the 4th quarter valued at approximately $11,604,000. Frazier Life Sciences Management L.P. lifted its holdings in shares of KalVista Pharmaceuticals by 32.5% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 4,887,867 shares of the specialty pharmaceutical company's stock worth $41,400,000 after acquiring an additional 1,200,000 shares during the period. Stempoint Capital LP acquired a new stake in shares of KalVista Pharmaceuticals during the 4th quarter worth approximately $8,409,000. Finally, Vestal Point Capital LP increased its stake in KalVista Pharmaceuticals by 19.3% in the fourth quarter. Vestal Point Capital LP now owns 4,770,000 shares of the specialty pharmaceutical company's stock valued at $40,402,000 after acquiring an additional 770,000 shares during the last quarter.
About KalVista Pharmaceuticals
(
Get Free Report)
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
Featured Articles
Before you consider KalVista Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and KalVista Pharmaceuticals wasn't on the list.
While KalVista Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
